Abstract:Dermatomyositis (DM) and polymyositis (PM) are idiopathic inflammatory myopathies with unknown etiology. The incidence of both diseases is estimated at 4 to 10 cases per million people per year.1 Classical DM patients display characteristic cutaneous manifestations, proximal muscle weakness, and laboratorial evidence of myositis. Skin manifestations include the classic periorbital heliotrope, cutaneous Gottron’s papules and signs, and violaceous erythema of the upper trunk and extremities. Muscle involvement may be revealed by elevated muscle-derived enzymes such as creatine kinase (CK), lactate dehydrogenase (LDH), aldolase, alanine aminotransferase (ALT) or aspartate transaminase (AST). Additional testing, including electromyography (EMG), magnetic resonance imaging (MRI), or even muscle biopsies, may be performed if other tests are inconclusive.2 Over the past decade, there has been increasing interest in a subset of patients with DM who may have had cutaneous manifestations of DM for 6 months or longer without any evidence of underlying myositis. This condition has been termed amyopathic DM (ADM), and considerable controversy exists regarding the nomenclature of ADM. In addition, some patients may present with skin lesions indicative of DM for 6 months or longer with no clinical muscle weakness but with some objective evidence of muscle inflammation, a condition sometimes referred to as hypomyopathic DM (HDM). Clinically amyopathic DM (CADM) encompasses patients who have either ADM or HDM.2 CADM is more common than what had been estimated previously and such patients may comprise a relatively high proportion of DM patients. Although the diseases primarily attack the skin and the muscles, pulmonary complications are increasingly recognized as a major cause of morbidity and mortality in patients with DM/PM. These complications include interstitial lung disease (ILD), aspiration pneumonia, ventilatory failure secondary to diaphragmatic dysfunction. ILD has been estimated to occur in 5%-65% of patients with DM/PM; its prevalence depends on different diagnostic methods (chest radiography, pulmonary function tests (PFTs), or high resolution computed tomography (HRCT) of the chest for screening), patient selection, and ethnic and geographic differences among the study populations. The reported prevalence of ILD in DM and PM may be increasing because of the awareness and knowledge about the diseases and the increasing availability of sensitive laboratory analyses.1 The systematic use of HRCT and PFTs in newly diagnosed PM and DM lead to the discovery of signs of ILD in as many as two thirds of patients.3 HRCT of the lungs have been considered to be a standard procedure for an initial evaluation of patients with suspected ILD.1 The clinical presentation of DM/PM patients with ILD varies. Based upon clinical symptoms and courses, patients have been described with three different clinical patterns: (1) acute or subacute type: patients present with severe, rapidly progressive dyspnea, with apparently progressive hypoxemia within several months from the onset of lung involvement, similar to patients with the Hamman-Rich syndrome; (2) chronic type: patients who present with slowly progressive symptoms; and (3) asymptomatic type: patients with ILD demonstrated by abnormal chest radiographs or pulmonary function tests in the absence of clinically apparent signs or symptoms.4 Early diagnosis and management of ILD may prevent the development of chronic pulmonary fibrosis, thereby prolonging patient survival and improving the quality of life.3 In addition, ILD may precede the diagnosis of DM in some patients; thus, particular attention should be paid to cutaneous changes in patients with ILD, such as heliotrope rash, facial erythema and edema, Gottron’s papules, and periungual telangiectasia.5 Since patients may have ILD without clinical symptoms, the risk factors that can predict ILD in DM, PM have been widely studied by rheumatologists, pulmonologists, and dermatologists. The strongest predictive factor for ILD in patients with DM and PM is the presence of antihistidyl transfer RNA (tRNA) synthetase antibodies, including anti-Jo-1 antibodies, but ILD may also be present in patients without these autoantibodies.1 Several studies demonstrated that the occurrence of ILD in DM/PM patients was closely correlated with Gottron’s papules, patients older than 40 years, arthralgia, and fever,4,6 while a conflicting study indicated that patients with Gottron’s papules are less likely to develop ILD.7 In this regard, in the current issue of the Chinese Medical Journal, Ji et al8 have addressed the aspects of the clinical presentation of ILD in patients with DM/PM. In a retrospective study of 197 patients, they found that older age at the onset, fever, arthritis/arthralgia, cardiac involvement, elevation of the first available ESR, and anti-Jo-1 antibodies positively correlated with ILD. A Hamman-Rich-like presentation, ADM-ILD, cardiac involvement, and hypoalbuminemia were poor prognostic factors for ILD-DM/PM. They also found that the outcome of ILD in ADM patients is usually progressive and poor. Unfortunately, due to the relatively small number of patients and data from a single center, there is currently no consensus about which risk factors can clearly predict ILD in DM/PM patients. The limitations of the study by Ji et al8 include its retrospective design and small ADM sample size (14 cases, accounting for 7.1% of the study patients). Since outpatients were not enrolled in their study, they might have underestimated the number of ADM patients. CADM and classical DM patients have similar associations with both malignancy and ILD.9 Several studies reported that rapidly progressive ILD were found in patients with CADM.10-12 It has been identified that a small number of CADM patients died of complications of ILD shortly after the onset of DM skin disease (less than 6 months) without ever experiencing muscle weakness. This subphenotype, referred to as “pre-myopathic DM,” requires a more systematic study. Dermatologists, the physicians most likely to treat these patients, should be aware of these distinctive variant patterns of DM and have a high index of suspicion for the development of pulmonary disease as early diagnosis and management can be lifesaving.9 Corticosteroid therapy is widely used in the treatment of DM/PM patients with or without ILD. However, corticosteroid as a single agent is often not sufficient for the improvement of ILD; thus, other immunosuppressive drugs or immune-modulating treatments are often required.1 However, the available information on treatment efficacy is based on a small selection of case series or case reports. The optimal treatment for DM/PM-associated ILD is still not well established and needs to be defined in large, prospective, randomized controlled therapeutic studies. Thus, all newly diagnosed patients with DM/PM, including asymptomatic ADM patients, should be examined for signs of ILD during the initial evaluation as well as during the follow-up to permit early diagnosis and appropriate management. This evaluation should include chest radiography, HRCT of the lungs, and PFTs.

When and How Should the Patients with Dermatomyositis Be Assessed for Interstitial Lung Disease?

Polymyositis and Dermatomyositis Biomarkers

Amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective study

Cytokines and chemokines in dermatomyositis

[A Clinical Analysis of Dermatomyositis with Interstitial Lung Disease in 20 Patients].

Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study

Clinical Nomogram Assisting in Discrimination of Juvenile Dermatomyositis-Associated Interstitial Lung Disease.

Clinical and Serological Feature S of Patients with Dermatomyositis Complicated by Spontaneous Pneumomediastinum

An Observational Study on the Clinical Characteristics and Prognosis of Patients With Interstitial Lung Disease Secondary to Dermatomyositis and Antisynthetase Syndrome

Predictive Factors and Unfavorable Prognostic Factorial Analysis of Interstitial Lung Disease in Patients with Inflammatory Myopathy

AB0845 The diagnostic and prognostic significance of anti-MDA5 antibody in dermatomyositis complicated interstitial lung disease in chinese

Measurement of Cytokines and Chemokines and Association with Clinical Severity of Dermatomyositis and Clinically Amyopathic Dermatomyositis.

[Clinical Features and Risk Factors Associated with Interstitial Lung Disease in Patients with Classic Dermatomyositis or Clinical Amyopathic Dermatomyositis].

The clinical and immunological feat ures of idiopathic inflammatory myopathy patients with rapid progressive interstitial lung disease

Clinical Analysis on the Features of Lung Diseases in Patients with Idiopathic Inflammatory Myositis

Factors Associated With Interstitial Lung Disease In Patients With Polymyositis And Dermatomyositis: A Systematic Review And Meta-Analysis

Risk Factors of Interstitial Lung Diseases in Clinically Amyopathic Dermatomyositis

Correlation of cytokines levels with interstitial lung disease in patients with inflammatory myopathy

The Predictive Factors and Unfavourable Prognostic Factors of Interstitial Lung Disease in Patients with Polymyositis/dermatomyositis

The clinical characteristics of interstitial lung disease in patients with dermatomyositis and polymyositis

Clinical Characteristics of and Risk Factors for Interstitial Lung Disease, Other Rheumatic Diseases and Malignancy in Adult Polymyositis and Dermatomyositis: A Retrospective Cohort Study